Sigma-Tau Industrie Farmaceutiche Riunite, S.P.A. v. Lonza, Ltd.

48 F. Supp. 2d 16, 1999 U.S. Dist. LEXIS 6642
District Court, District of Columbia·Decided February 23, 1999·No. Civil Action 970562JHG/DAR·Published·Cited by 2 cases

Opinion

MEMORANDUM ORDER

DEBORAH ANN ROBINSON, United States Magistrate Judge.

This is a declaratory judgment action in which plaintiffs seek a determination that U.S. Patent No. 5,073,376 (the “L-carnitine L-tartrate patent” or the “ ’376 patent”) is invalid and not infringed by virtue of a product which plaintiffs manufacture and sell in Europe, but have not sold in the United States since 1996. During the course of discovery, plaintiffs took the deposition of Stephen Blum, a co-inventor of U.S. Patent No. 5,030,657 (the “catfish pat *17 ent”) and, at the time of the deposition, an employee of defendant.

After the close of discovery, plaintiffs sought leave to reopen discovery and to redepose Mr. Blum and conduct follow-up discovery with respect to his corrections of his deposition testimony. See Plaintiffs’ Motion for Leave to Reopen Discovery to Redepose Stephen Blum and Conduct Discovery of Matters Raised Therein. By an Order entered on July 27, 1998, the trial court granted the motion. The trial court found that “Mr. Blum did not respond accurately and completely to the questions posed at his deposition[,]” and that “the significantly different answers now proposed by Mr. Blum ... [are] ample justification for plaintiffs’ request to re-depose Mr. Blum.” July 27, 1998 Order at 2. By the same Order, the trial court referred to the undersigned any disputes between the parties regarding the reasonableness of the follow-up discovery. July 27, 1998 Order at 3. In a subsequent Order, the trial court referred to the undersigned for resolution the plaintiffs’ allegations that defense counsel caused the re-deposition by instructing Mr. Blum to lie, to withhold information and not to correct his original deposition testimony. September 16, 1998 Order at 2; see Plaintiffs’ Supplemental Opposition to Defendant’s Motion for Partial Reconsideration of the Order Granting Leave to Reopen Discovery to Re-Depose Stephen Blum and Conduct Discovery of Matters Raised Therein at 2-3.

I.

These and other allegations of misconduct by both defendant and its counsel are the subject of Plaintiffs’ Motion to Compel Production of Withheld Documents and Testimony Under the Crime-Fraud Exception to the Attorney-Client Privilege and Work Product Immunity Doctrine (Docket No. 117). In the memorandum in support of the motion, plaintiffs maintained that the testimony of Mr. Blum when he was re-deposed “revealed a shocking patter of fraud and deceit by defendant and defense counsel[.]” Plaintiffs’ Memorandum in Support of Their Motion to Compel Production of Withheld Documents and Testimony Under the Crime-Fraud Exception to the Attorney-Client Privilege and Work Product Immunity Doctrine (“Plaintiffs’ Memorandum in Support of Motion”) at 1. More specifically, plaintiffs alleged (1) that defendant and its counsel, Bert Lewen and David Francesca-ni, “forced” Mr. Blum to lie when he was first deposed; (2) that Mr. Lewen should have known that Mr. Blum was providing inaccurate answers when he was first deposed, but never “instructed” Mr. Blum to correct his answers; and (3) that Mr. Lew-en and an associate, Maryann Hayes, “denied [Mr. Blum] the opportunity” to correct his testimony when he appealed to them for assistance in doing so. Plaintiffs’ Memorandum in Support of Motion at 1-2. Plaintiffs maintained that Mr. Blum’s testimony “provides ... a prima facie case to seek the abrogation of the attorney-client privilege and the work-product immunity in this case as it relates to the preparation, prosecution, enforcement and/or defense of [the ’376 patent] and any foreign counterparts thereof.” Plaintiffs’ Memorandum in Support of Motion at 2. In its opposition to plaintiffs’ motion to compel, defendant characterized Mr. Blum’s allegations as “totally untrue[,]” and part of “the ever-changing testimony of a disgruntled ex-employee under psychiatric care and under the influence of psycho-active medication[.]” Defendant’s Memorandum in Opposition to Plaintiffs’ Motion to Compel Production of Documents and Testimony Under the Crime-Fraud Exception and in Support of Defendant’s Cross Motions for a Pretrial Conference to Resolve the Issues Raised by the Blum Deposition and for a Protective Order (“Defendant’s Opposition to Motion”) at 1. However, defendant conceded that the allegations were “sufficiently serious that they must be resolved prior to trial[,]” and sought a pretrial conference at which a procedure for resolution of the allegations could be established. Defendant’s Opposition to Mo *18 tion at 2-3. Plaintiffs subsequently joined in defendant’s request for a pretrial conference to establish a procedure for exploring the allegations of fraud raised by Mr. Blum. See Plaintiffs’ Reply to Defendant’s Opposition to Plaintiffs’ Motion to Compel Production of Withheld Documents and Testimony Under the Crime-Fraud Exception and Plaintiffs’ Response to Defendant’s Cross Motions for a Pretrial Conference to Establish a Procedure to Resolve the Issues Raised by the Blum Deposition and for a Protective Order at 2.

Counsel for the parties appeared before the undersigned for the conference on September 23, 1998. The parties’ agreement regarding the extent and scope of discovery, as well as the identities of the witnesses who would appear for the hearing on plaintiffs’ motion to compel, was included in a proposed order prepared by counsel for the parties, and signed by the undersigned. See September 23, 1998 Order Regarding the Extent and Scope of Discovery Related to Plaintiffs’ Motion to Compel Production of Withheld Documents and Testimony Under the Crime-Fraud Exception. The parties were directed to file pre-hearing memoranda on December 4, 1998, and the hearing on plaintiffs’ motion to compel was scheduled for December 10, 1998. The parties jointly requested, and the undersigned allowed, one brief extension of discovery. See October 27, 1998 Order. The parties also agreed to the format for the exchange of exhibits and order of witnesses at the hearing. See December 9, 1998 Consent Order Regarding the Format for the Hearing Before the Court on December 10-11,1998.

In their pre-hearing memoranda, the parties, relying largely upon the testimony and other evidence obtained during the discovery conducted in accordance with the undersigned’s September 23, 1998 Order, urged varying interpretations of such evidence. Plaintiffs alleged (1) that Mr. Lew-en committed fraud on this Court when he failed to advise Mr. Blum to correct his testimony or to advise this Court of Mr. Blum’s perjury; and (2) that Mr. Lewen committed an additional act of fraud on this Court by taking a position regarding the patentability of the catfish patent which he knew was incorrect. See Plaintiffs’ Memorandum of Law Regarding Discovery Relating to the Issue of Fraud on the Court (“Plaintiffs’ Pre-Hearing Memorandum”) at 8-17. Plaintiffs maintained that the discovery obtained with respect to those allegations — particularly the testimony of Mr. Blum — “presents a prima facie case of fraud on this Court sufficient to pierce the attorney-client privilege.” Plaintiffs’ Pre-Hearing Memorandum at 17.

Defendant, on the other hand, alleged that “Blum ...

Free access — add to your briefcase to read the full text and ask questions with AI

Sigma-Tau Industrie Farmaceutiche Riunite, S.P.A. v. Lonza, Ltd., 48 F. Supp. 2d 16, 1999 U.S. Dist. LEXIS 6642 (D.D.C. 1999).

48 F. Supp. 2d 16 (Sigma-Tau Industrie Farmaceutiche Riunite, S.P.A. v. Lonza, Ltd.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Gutter v. E.I. Dupont De Nemours
124 F. Supp. 2d 1291 (S.D. Florida, 2000)
Sigma-Tau Industrie Framaceutiche Riunite, S.P.A. v. Lonza, Ltd.
106 F. Supp. 2d 8 (District of Columbia, 2000)